Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| INSULET CORPPODD · Entity 3516 | Director | May 20, 2026 | May 21, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
INSULET CORP
Report date May 20, 2026 · Filed May 21, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 2,438 |
Reported balance
After 2026-05-20 transaction · row 1
1 source rowRow 1 · 2026-05-20 · Grant · Acquired 1,660 · Balance 2,438 F1: Annual equity award in the form of restricted stock units ("RSUs"). These RSUs, which will be settled in shares of common stock on a one-for-one basis, vest in full on April 30, 2027. |
| Common StockSEC Table I · non-derivative | IndirectBy Trust | 17,483 |
Reported balance
Holding disclosure · report date 2026-05-20 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 17,483 |
Filing footnotes · ownership attribution and instrument terms
F1: Annual equity award in the form of restricted stock units ("RSUs"). These RSUs, which will be settled in shares of common stock on a one-for-one basis, vest in full on April 30, 2027.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
ABIOMED INC
Report date December 22, 2022 · Filed December 27, 2022
Section 16 reporting ended · disclosed 2022-12-27. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock $.01 par valueSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2022-12-22 transaction · row 1
1 source rowRow 1 · 2022-12-22 · Disposition to issuer · Disposed 166,670 · Balance 0 F1: Disposed in connection with transactions contemplated by the Agreement and Plan of Merger, dated as of October 31, 2022 (the "Merger Agreement"), by and among the Issuer, Johnson & Johnson ("Parent") and Athos Merger Sub, Inc. ("Merger Sub"), pursuant to which, on December 22, 2022, Merger Sub was merged with and into the Issuer (the "Merger"), with the Issuer surviving the Merger as a wholly owned subsidiary of Parent. As a result of the Merger, each outstanding share of common stock, par value $0.01 per share, of the Issuer (each, an "Issuer Share") was automatically converted into the right to receive (i) an amount in cash equal to $380.00 (the "Cash Amount"), plus (ii) one non-tradeable contingent value right (the "CVR"), representing the right to receive contingent payments of up to $35.00 per Issuer Share, payable upon the achievement of certain specified milestones set out in the Contingent Value Rights Agreement. F2: Pursuant to the Merger Agreement, each award of restricted stock units of the Issuer, excluding any award of restricted stock units with vesting subject to performance-based conditions ("Company RSU Award"), outstanding as of immediately prior to the Effective Time was canceled and converted into the right to receive (i) an amount in cash, without interest, equal to the product of (A) the aggregate number of Issuer Shares underlying such Company RSU Award and (B) the Cash Amount and (ii) one CVR per Issuer Share. F3: This number reflects unvested Company RSU Awards and shares of common stock. The Form 4 filed on December 20, 2022 for Michael Minogue inadvertently omitted unvested Company RSU Awards from the balance of non-derivative securities beneficially owned by the reporting person. |
| Common Stock $.01 par valueSEC Table I · non-derivative | IndirectBy Trust | 0 |
Reported balance
After 2022-12-22 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2022-12-22 · Disposition to issuer · Disposed 243,962 · Balance 0 F1: Disposed in connection with transactions contemplated by the Agreement and Plan of Merger, dated as of October 31, 2022 (the "Merger Agreement"), by and among the Issuer, Johnson & Johnson ("Parent") and Athos Merger Sub, Inc. ("Merger Sub"), pursuant to which, on December 22, 2022, Merger Sub was merged with and into the Issuer (the "Merger"), with the Issuer surviving the Merger as a wholly owned subsidiary of Parent. As a result of the Merger, each outstanding share of common stock, par value $0.01 per share, of the Issuer (each, an "Issuer Share") was automatically converted into the right to receive (i) an amount in cash equal to $380.00 (the "Cash Amount"), plus (ii) one non-tradeable contingent value right (the "CVR"), representing the right to receive contingent payments of up to $35.00 per Issuer Share, payable upon the achievement of certain specified milestones set out in the Contingent Value Rights Agreement. F3: This number reflects unvested Company RSU Awards and shares of common stock. The Form 4 filed on December 20, 2022 for Michael Minogue inadvertently omitted unvested Company RSU Awards from the balance of non-derivative securities beneficially owned by the reporting person. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $21.55 · Expires 2024-05-14 | Direct | 0 |
Reported balance
After 2022-12-22 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2022-12-22 · Disposition to issuer · Disposed 85,000 · Balance 0 F4: Pursuant to the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each option to purchase Issuer Shares that was outstanding and unexercised immediately prior to the Effective Time was canceled and converted into the right to receive: (1) with respect to each stock option with a per share exercise price less than the Cash Amount (an "In-the-Money Option"), (A) an amount in cash, without interest, equal to the product of (I) the aggregate number of Issuer Shares underlying such In-the-Money Option and (II) the excess, if any, of (x) the Cash Amount over (y) the per share exercise price of such In-the-Money Option and (B) one CVR per Issuer Share underlying such In-the-Money Option; F5: ; and (2) with respect to each stock option with a per share exercise price that was greater than or equal to the Cash Amount (an "Out-of-the-Money option"), upon each Valuation Point (as defined in the Merger Agreement) occurring after the Effective Time, an amount in cash, without interest, equal to the product of (A) the aggregate number of Issuer Shares underlying such Out-of-the-Money Option and (B) (I) the excess, if any, of (x) the Per Share Value Paid (as defined in the Merger Agreement) as of such Valuation Point over (y) the per share exercise price of such Out-of-the-Money Option, less (II) the amount of all payments previously received with respect to such Out-of-the-Money Option. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $66.25 · Expires 2025-05-13 | Direct | 0 |
Reported balance
After 2022-12-22 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2022-12-22 · Disposition to issuer · Disposed 35,000 · Balance 0 F4: Pursuant to the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each option to purchase Issuer Shares that was outstanding and unexercised immediately prior to the Effective Time was canceled and converted into the right to receive: (1) with respect to each stock option with a per share exercise price less than the Cash Amount (an "In-the-Money Option"), (A) an amount in cash, without interest, equal to the product of (I) the aggregate number of Issuer Shares underlying such In-the-Money Option and (II) the excess, if any, of (x) the Cash Amount over (y) the per share exercise price of such In-the-Money Option and (B) one CVR per Issuer Share underlying such In-the-Money Option; F5: ; and (2) with respect to each stock option with a per share exercise price that was greater than or equal to the Cash Amount (an "Out-of-the-Money option"), upon each Valuation Point (as defined in the Merger Agreement) occurring after the Effective Time, an amount in cash, without interest, equal to the product of (A) the aggregate number of Issuer Shares underlying such Out-of-the-Money Option and (B) (I) the excess, if any, of (x) the Per Share Value Paid (as defined in the Merger Agreement) as of such Valuation Point over (y) the per share exercise price of such Out-of-the-Money Option, less (II) the amount of all payments previously received with respect to such Out-of-the-Money Option. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $99.62 · Expires 2026-05-24 | Direct | 0 |
Reported balance
After 2022-12-22 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2022-12-22 · Disposition to issuer · Disposed 30,500 · Balance 0 F4: Pursuant to the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each option to purchase Issuer Shares that was outstanding and unexercised immediately prior to the Effective Time was canceled and converted into the right to receive: (1) with respect to each stock option with a per share exercise price less than the Cash Amount (an "In-the-Money Option"), (A) an amount in cash, without interest, equal to the product of (I) the aggregate number of Issuer Shares underlying such In-the-Money Option and (II) the excess, if any, of (x) the Cash Amount over (y) the per share exercise price of such In-the-Money Option and (B) one CVR per Issuer Share underlying such In-the-Money Option; F5: ; and (2) with respect to each stock option with a per share exercise price that was greater than or equal to the Cash Amount (an "Out-of-the-Money option"), upon each Valuation Point (as defined in the Merger Agreement) occurring after the Effective Time, an amount in cash, without interest, equal to the product of (A) the aggregate number of Issuer Shares underlying such Out-of-the-Money Option and (B) (I) the excess, if any, of (x) the Per Share Value Paid (as defined in the Merger Agreement) as of such Valuation Point over (y) the per share exercise price of such Out-of-the-Money Option, less (II) the amount of all payments previously received with respect to such Out-of-the-Money Option. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $134.51 · Expires 2027-05-15 | Direct | 0 |
Reported balance
After 2022-12-22 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2022-12-22 · Disposition to issuer · Disposed 33,000 · Balance 0 F4: Pursuant to the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each option to purchase Issuer Shares that was outstanding and unexercised immediately prior to the Effective Time was canceled and converted into the right to receive: (1) with respect to each stock option with a per share exercise price less than the Cash Amount (an "In-the-Money Option"), (A) an amount in cash, without interest, equal to the product of (I) the aggregate number of Issuer Shares underlying such In-the-Money Option and (II) the excess, if any, of (x) the Cash Amount over (y) the per share exercise price of such In-the-Money Option and (B) one CVR per Issuer Share underlying such In-the-Money Option; F5: ; and (2) with respect to each stock option with a per share exercise price that was greater than or equal to the Cash Amount (an "Out-of-the-Money option"), upon each Valuation Point (as defined in the Merger Agreement) occurring after the Effective Time, an amount in cash, without interest, equal to the product of (A) the aggregate number of Issuer Shares underlying such Out-of-the-Money Option and (B) (I) the excess, if any, of (x) the Per Share Value Paid (as defined in the Merger Agreement) as of such Valuation Point over (y) the per share exercise price of such Out-of-the-Money Option, less (II) the amount of all payments previously received with respect to such Out-of-the-Money Option. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $381.97 · Expires 2028-05-16 | Direct | 0 |
Reported balance
After 2022-12-22 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2022-12-22 · Disposition to issuer · Disposed 30,000 · Balance 0 F4: Pursuant to the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each option to purchase Issuer Shares that was outstanding and unexercised immediately prior to the Effective Time was canceled and converted into the right to receive: (1) with respect to each stock option with a per share exercise price less than the Cash Amount (an "In-the-Money Option"), (A) an amount in cash, without interest, equal to the product of (I) the aggregate number of Issuer Shares underlying such In-the-Money Option and (II) the excess, if any, of (x) the Cash Amount over (y) the per share exercise price of such In-the-Money Option and (B) one CVR per Issuer Share underlying such In-the-Money Option; F5: ; and (2) with respect to each stock option with a per share exercise price that was greater than or equal to the Cash Amount (an "Out-of-the-Money option"), upon each Valuation Point (as defined in the Merger Agreement) occurring after the Effective Time, an amount in cash, without interest, equal to the product of (A) the aggregate number of Issuer Shares underlying such Out-of-the-Money Option and (B) (I) the excess, if any, of (x) the Per Share Value Paid (as defined in the Merger Agreement) as of such Valuation Point over (y) the per share exercise price of such Out-of-the-Money Option, less (II) the amount of all payments previously received with respect to such Out-of-the-Money Option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $266.39 · Expires 2029-05-30 | Direct | 0 |
Reported balance
After 2022-12-22 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2022-12-22 · Disposition to issuer · Disposed 50,000 · Balance 0 F4: Pursuant to the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each option to purchase Issuer Shares that was outstanding and unexercised immediately prior to the Effective Time was canceled and converted into the right to receive: (1) with respect to each stock option with a per share exercise price less than the Cash Amount (an "In-the-Money Option"), (A) an amount in cash, without interest, equal to the product of (I) the aggregate number of Issuer Shares underlying such In-the-Money Option and (II) the excess, if any, of (x) the Cash Amount over (y) the per share exercise price of such In-the-Money Option and (B) one CVR per Issuer Share underlying such In-the-Money Option; F5: ; and (2) with respect to each stock option with a per share exercise price that was greater than or equal to the Cash Amount (an "Out-of-the-Money option"), upon each Valuation Point (as defined in the Merger Agreement) occurring after the Effective Time, an amount in cash, without interest, equal to the product of (A) the aggregate number of Issuer Shares underlying such Out-of-the-Money Option and (B) (I) the excess, if any, of (x) the Per Share Value Paid (as defined in the Merger Agreement) as of such Valuation Point over (y) the per share exercise price of such Out-of-the-Money Option, less (II) the amount of all payments previously received with respect to such Out-of-the-Money Option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $223.90 · Expires 2030-05-29 | Direct | 0 |
Reported balance
After 2022-12-22 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2022-12-22 · Disposition to issuer · Disposed 20,898 · Balance 0 F4: Pursuant to the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each option to purchase Issuer Shares that was outstanding and unexercised immediately prior to the Effective Time was canceled and converted into the right to receive: (1) with respect to each stock option with a per share exercise price less than the Cash Amount (an "In-the-Money Option"), (A) an amount in cash, without interest, equal to the product of (I) the aggregate number of Issuer Shares underlying such In-the-Money Option and (II) the excess, if any, of (x) the Cash Amount over (y) the per share exercise price of such In-the-Money Option and (B) one CVR per Issuer Share underlying such In-the-Money Option; F5: ; and (2) with respect to each stock option with a per share exercise price that was greater than or equal to the Cash Amount (an "Out-of-the-Money option"), upon each Valuation Point (as defined in the Merger Agreement) occurring after the Effective Time, an amount in cash, without interest, equal to the product of (A) the aggregate number of Issuer Shares underlying such Out-of-the-Money Option and (B) (I) the excess, if any, of (x) the Per Share Value Paid (as defined in the Merger Agreement) as of such Valuation Point over (y) the per share exercise price of such Out-of-the-Money Option, less (II) the amount of all payments previously received with respect to such Out-of-the-Money Option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $283.88 · Expires 2031-05-25 | Direct | 0 |
Reported balance
After 2022-12-22 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2022-12-22 · Disposition to issuer · Disposed 30,000 · Balance 0 F4: Pursuant to the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each option to purchase Issuer Shares that was outstanding and unexercised immediately prior to the Effective Time was canceled and converted into the right to receive: (1) with respect to each stock option with a per share exercise price less than the Cash Amount (an "In-the-Money Option"), (A) an amount in cash, without interest, equal to the product of (I) the aggregate number of Issuer Shares underlying such In-the-Money Option and (II) the excess, if any, of (x) the Cash Amount over (y) the per share exercise price of such In-the-Money Option and (B) one CVR per Issuer Share underlying such In-the-Money Option; F5: ; and (2) with respect to each stock option with a per share exercise price that was greater than or equal to the Cash Amount (an "Out-of-the-Money option"), upon each Valuation Point (as defined in the Merger Agreement) occurring after the Effective Time, an amount in cash, without interest, equal to the product of (A) the aggregate number of Issuer Shares underlying such Out-of-the-Money Option and (B) (I) the excess, if any, of (x) the Per Share Value Paid (as defined in the Merger Agreement) as of such Valuation Point over (y) the per share exercise price of such Out-of-the-Money Option, less (II) the amount of all payments previously received with respect to such Out-of-the-Money Option. |
| Performance Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 96,265 |
Reported balance
After 2022-12-22 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2022-12-22 · Grant · Acquired 96,265 · Balance 96,265 F6: Pursuant to the Merger Agreement, each award of restricted stock units with vesting subject to performance-based conditions ("Company PSU Award") outstanding immediately prior to the Effective Time was canceled and converted into the right to receive (i) an amount in cash, without interest, equal to the product of (A) the aggregate number of Issuer Shares underlying such Company PSU Award (assuming (1) the actual level of performance for performance metrics for which the relevant performance period has been completed as of December 22, 2022 (the "Closing Date") and (2) the maximum level of performance under the terms of the applicable award agreement as in effect on the date of the Merger Agreement for performance metrics for which the relevant performance period has not been completed as of the Closing Date (subject, in the case of Company PSU Awards granted to the Chief Executive Officer of the Company, to a maximum level of performance of 200% of the target level of performance) F7: and (B) the Cash Amount, and (ii) one CVR for each Issuer Share underlying such Company PSU Award (assuming (1) the actual level of performance for performance metrics for which the relevant performance period has been completed as of the Closing Date and (2) the maximum level of performance under the terms of the applicable award agreement as in effect on the date of the Merger Agreement for performance metrics for which the relevant performance period has not been completed as the Closing Date (subject, in the case of Company PSU Awards granted to the Chief Executive Officer of the Company, to a maximum level of performance of 200% of the target level of performance)). |
| Performance Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2022-12-22 transaction · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · 2022-12-22 · Disposition to issuer · Disposed 96,265 · Balance 0 F6: Pursuant to the Merger Agreement, each award of restricted stock units with vesting subject to performance-based conditions ("Company PSU Award") outstanding immediately prior to the Effective Time was canceled and converted into the right to receive (i) an amount in cash, without interest, equal to the product of (A) the aggregate number of Issuer Shares underlying such Company PSU Award (assuming (1) the actual level of performance for performance metrics for which the relevant performance period has been completed as of December 22, 2022 (the "Closing Date") and (2) the maximum level of performance under the terms of the applicable award agreement as in effect on the date of the Merger Agreement for performance metrics for which the relevant performance period has not been completed as of the Closing Date (subject, in the case of Company PSU Awards granted to the Chief Executive Officer of the Company, to a maximum level of performance of 200% of the target level of performance) F7: and (B) the Cash Amount, and (ii) one CVR for each Issuer Share underlying such Company PSU Award (assuming (1) the actual level of performance for performance metrics for which the relevant performance period has been completed as of the Closing Date and (2) the maximum level of performance under the terms of the applicable award agreement as in effect on the date of the Merger Agreement for performance metrics for which the relevant performance period has not been completed as the Closing Date (subject, in the case of Company PSU Awards granted to the Chief Executive Officer of the Company, to a maximum level of performance of 200% of the target level of performance)). |
Filing footnotes · ownership attribution and instrument terms
F1: Disposed in connection with transactions contemplated by the Agreement and Plan of Merger, dated as of October 31, 2022 (the "Merger Agreement"), by and among the Issuer, Johnson & Johnson ("Parent") and Athos Merger Sub, Inc. ("Merger Sub"), pursuant to which, on December 22, 2022, Merger Sub was merged with and into the Issuer (the "Merger"), with the Issuer surviving the Merger as a wholly owned subsidiary of Parent. As a result of the Merger, each outstanding share of common stock, par value $0.01 per share, of the Issuer (each, an "Issuer Share") was automatically converted into the right to receive (i) an amount in cash equal to $380.00 (the "Cash Amount"), plus (ii) one non-tradeable contingent value right (the "CVR"), representing the right to receive contingent payments of up to $35.00 per Issuer Share, payable upon the achievement of certain specified milestones set out in the Contingent Value Rights Agreement.
F2: Pursuant to the Merger Agreement, each award of restricted stock units of the Issuer, excluding any award of restricted stock units with vesting subject to performance-based conditions ("Company RSU Award"), outstanding as of immediately prior to the Effective Time was canceled and converted into the right to receive (i) an amount in cash, without interest, equal to the product of (A) the aggregate number of Issuer Shares underlying such Company RSU Award and (B) the Cash Amount and (ii) one CVR per Issuer Share.
F3: This number reflects unvested Company RSU Awards and shares of common stock. The Form 4 filed on December 20, 2022 for Michael Minogue inadvertently omitted unvested Company RSU Awards from the balance of non-derivative securities beneficially owned by the reporting person.
F4: Pursuant to the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each option to purchase Issuer Shares that was outstanding and unexercised immediately prior to the Effective Time was canceled and converted into the right to receive: (1) with respect to each stock option with a per share exercise price less than the Cash Amount (an "In-the-Money Option"), (A) an amount in cash, without interest, equal to the product of (I) the aggregate number of Issuer Shares underlying such In-the-Money Option and (II) the excess, if any, of (x) the Cash Amount over (y) the per share exercise price of such In-the-Money Option and (B) one CVR per Issuer Share underlying such In-the-Money Option;
F5: ; and (2) with respect to each stock option with a per share exercise price that was greater than or equal to the Cash Amount (an "Out-of-the-Money option"), upon each Valuation Point (as defined in the Merger Agreement) occurring after the Effective Time, an amount in cash, without interest, equal to the product of (A) the aggregate number of Issuer Shares underlying such Out-of-the-Money Option and (B) (I) the excess, if any, of (x) the Per Share Value Paid (as defined in the Merger Agreement) as of such Valuation Point over (y) the per share exercise price of such Out-of-the-Money Option, less (II) the amount of all payments previously received with respect to such Out-of-the-Money Option.
F6: Pursuant to the Merger Agreement, each award of restricted stock units with vesting subject to performance-based conditions ("Company PSU Award") outstanding immediately prior to the Effective Time was canceled and converted into the right to receive (i) an amount in cash, without interest, equal to the product of (A) the aggregate number of Issuer Shares underlying such Company PSU Award (assuming (1) the actual level of performance for performance metrics for which the relevant performance period has been completed as of December 22, 2022 (the "Closing Date") and (2) the maximum level of performance under the terms of the applicable award agreement as in effect on the date of the Merger Agreement for performance metrics for which the relevant performance period has not been completed as of the Closing Date (subject, in the case of Company PSU Awards granted to the Chief Executive Officer of the Company, to a maximum level of performance of 200% of the target level of performance)
F7: and (B) the Cash Amount, and (ii) one CVR for each Issuer Share underlying such Company PSU Award (assuming (1) the actual level of performance for performance metrics for which the relevant performance period has been completed as of the Closing Date and (2) the maximum level of performance under the terms of the applicable award agreement as in effect on the date of the Merger Agreement for performance metrics for which the relevant performance period has not been completed as the Closing Date (subject, in the case of Company PSU Awards granted to the Chief Executive Officer of the Company, to a maximum level of performance of 200% of the target level of performance)).
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 20, 2026 Filed May 21, 2026 20:36 UTC | INSULET CORP PODD · Entity 3516 | GrantCommon Stock | 1,660 | $0.00 | $0.00 |
DisclosureSEC source: 0001145197-26-000126 · form4.xml · nonDerivative · entry 1 MINOGUE MICHAEL R · CIK 0001286370 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,438 F1 · shares: Annual equity award in the form of restricted stock units ("RSUs"). These RSUs, which will be settled in shares of common stock on a one-for-one basis, vest in full on April 30, 2027. Read SEC document |
| February 25, 2026 Filed Feb 26, 2026 12:05 UTC | INSULET CORP PODD · Entity 3516 | PurchaseCommon Stock | 2,030 | $246.23 | $499,846.90 |
DisclosureSEC source: 0001145197-26-000044 · form4.xml · nonDerivative · entry 1 MINOGUE MICHAEL R · CIK 0001286370 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Trust Disclosed balance after: 17,483 F1 · price: The price reported represents the weighted average purchase price of the shares acquired. The shares were purchased in multiple transactions at prices ranging from $246.04 to $246.42. The Reporting Person hereby undertakes, upon the request of the Staff of the U.S. Securities Exchange Commission, the Issuer or a security holder of the Issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| August 21, 2025 Filed Aug 21, 2025 20:11 UTC | INSULET CORP PODD · Entity 3516 | GiftCommon Stock | 1,380 | $0.00 | $0.00 |
DisclosureSEC source: 0001145197-25-000046 · form4.xml · nonDerivative · entry 6 MINOGUE MICHAEL R · CIK 0001286370 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Trust Disclosed balance after: 15,453 F2 · shares: This transaction represents the transfer of common stock by bona fide gift from the reporting person to a trust held for the benefit of the reporting person's spouse. The reporting person's spouse is a trustee of the trust. Read SEC document |
| August 21, 2025 Filed Aug 21, 2025 20:11 UTC | INSULET CORP PODD · Entity 3516 | GiftCommon Stock | 1,380 | $0.00 | $0.00 |
DisclosureSEC source: 0001145197-25-000046 · form4.xml · nonDerivative · entry 5 MINOGUE MICHAEL R · CIK 0001286370 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 778 F2 · shares: This transaction represents the transfer of common stock by bona fide gift from the reporting person to a trust held for the benefit of the reporting person's spouse. The reporting person's spouse is a trustee of the trust. Read SEC document |
| August 19, 2025 Filed Aug 21, 2025 20:11 UTC | INSULET CORP PODD · Entity 3516 | GiftCommon Stock | 9,459 | $0.00 | $0.00 |
DisclosureSEC source: 0001145197-25-000046 · form4.xml · nonDerivative · entry 4 MINOGUE MICHAEL R · CIK 0001286370 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Trust Disclosed balance after: 14,073 F2 · shares: This transaction represents the transfer of common stock by bona fide gift from the reporting person to a trust held for the benefit of the reporting person's spouse. The reporting person's spouse is a trustee of the trust. Read SEC document |
| August 19, 2025 Filed Aug 21, 2025 20:11 UTC | INSULET CORP PODD · Entity 3516 | GiftCommon Stock | 9,459 | $0.00 | $0.00 |
DisclosureSEC source: 0001145197-25-000046 · form4.xml · nonDerivative · entry 3 MINOGUE MICHAEL R · CIK 0001286370 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,158 F2 · shares: This transaction represents the transfer of common stock by bona fide gift from the reporting person to a trust held for the benefit of the reporting person's spouse. The reporting person's spouse is a trustee of the trust. Read SEC document |
| August 19, 2025 Filed Aug 21, 2025 20:11 UTC | INSULET CORP PODD · Entity 3516 | GiftCommon Stock | 9,459 | $0.00 | $0.00 |
DisclosureSEC source: 0001145197-25-000046 · form4.xml · nonDerivative · entry 2 MINOGUE MICHAEL R · CIK 0001286370 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,617 F1 · shares: This transaction represents the transfer of common stock from the GRAT to the reporting person. Read SEC document |
| August 19, 2025 Filed Aug 21, 2025 20:11 UTC | INSULET CORP PODD · Entity 3516 | GiftCommon Stock | 9,459 | $0.00 | $0.00 |
DisclosureSEC source: 0001145197-25-000046 · form4.xml · nonDerivative · entry 1 MINOGUE MICHAEL R · CIK 0001286370 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By GRAT Disclosed balance after: 0 F1 · shares: This transaction represents the transfer of common stock from the GRAT to the reporting person. Read SEC document |
| May 22, 2025 Filed May 27, 2025 20:08 UTC | INSULET CORP PODD · Entity 3516 | GrantCommon Stock | 778 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-25-015651 · form4.xml · nonDerivative · entry 1 MINOGUE MICHAEL R · CIK 0001286370 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,158 F1 · shares: Annual equity award in the form of restricted stock units ("RSUs"). These RSUs, which will be settled in shares of common stock on a one-for-one basis, vest in full on April 30, 2026. Read SEC document |
| June 04, 2024 Filed Jun 5, 2024 20:15 UTC | INSULET CORP PODD · Entity 3516 | GiftCommon Stock | 843 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-017916 · form4.xml · nonDerivative · entry 2 MINOGUE MICHAEL R · CIK 0001286370 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Trust Disclosed balance after: 4,614 F1 · shares: This transaction represents the transfer of common stock by bona fide gift from the reporting person to a trust held for the benefit of the reporting person's spouse. The reporting person's spouse is a trustee of the trust. Read SEC document |
| June 04, 2024 Filed Jun 5, 2024 20:15 UTC | INSULET CORP PODD · Entity 3516 | GiftCommon Stock | 843 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-017916 · form4.xml · nonDerivative · entry 1 MINOGUE MICHAEL R · CIK 0001286370 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,380 F1 · shares: This transaction represents the transfer of common stock by bona fide gift from the reporting person to a trust held for the benefit of the reporting person's spouse. The reporting person's spouse is a trustee of the trust. Read SEC document |
| May 22, 2024 Filed May 23, 2024 21:10 UTC | INSULET CORP PODD · Entity 3516 | GrantCommon Stock | 1,380 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-016460 · form4.xml · nonDerivative · entry 1 MINOGUE MICHAEL R · CIK 0001286370 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,223 F1 · shares: Annual equity award in the form of restricted stock units ("RSUs"). These RSUs vest in full on April 30, 2025 and are settled in shares of common stock on a one-for-one basis. Read SEC document |
| August 18, 2023 Filed Aug 18, 2023 20:26 UTC | INSULET CORP PODD · Entity 3516 | GiftCommon Stock | 8,450 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-022944 · form4.xml · nonDerivative · entry 4 MINOGUE MICHAEL R · CIK 0001286370 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By GRAT Disclosed balance after: 9,459 Read SEC document |
| August 18, 2023 Filed Aug 18, 2023 20:26 UTC | INSULET CORP PODD · Entity 3516 | GiftCommon Stock | 8,450 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-022944 · form4.xml · nonDerivative · entry 3 MINOGUE MICHAEL R · CIK 0001286370 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Trust Disclosed balance after: 3,771 Read SEC document |
| August 17, 2023 Filed Aug 18, 2023 20:26 UTC | INSULET CORP PODD · Entity 3516 | GiftCommon Stock | 1,009 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-022944 · form4.xml · nonDerivative · entry 2 MINOGUE MICHAEL R · CIK 0001286370 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By GRAT Disclosed balance after: 1,009 Read SEC document |
| August 17, 2023 Filed Aug 18, 2023 20:26 UTC | INSULET CORP PODD · Entity 3516 | GiftCommon Stock | 1,009 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-022944 · form4.xml · nonDerivative · entry 1 MINOGUE MICHAEL R · CIK 0001286370 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 843 Read SEC document |
| May 23, 2023 Filed May 24, 2023 20:11 UTC | INSULET CORP PODD · Entity 3516 | GrantCommon Stock | 843 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-016714 · form4.xml · nonDerivative · entry 2 MINOGUE MICHAEL R · CIK 0001286370 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,852 F2 · shares: Annual equity award in the form of restricted stock units ("RSUs"). These RSUs vest in full on April 30, 2024 and are settled in shares of common stock on a one-for-one basis. Read SEC document |
| May 23, 2023 Filed May 24, 2023 20:11 UTC | INSULET CORP PODD · Entity 3516 | PurchaseCommon Stock | 3,300 | $304.75 | $1,005,675.00 |
DisclosureSEC source: 0001127602-23-016714 · form4.xml · nonDerivative · entry 1 MINOGUE MICHAEL R · CIK 0001286370 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Trust Disclosed balance after: 12,221 F1 · price: The price reported represents the weighted average purchase price of the shares bought. The shares were bought at varying prices in the range of $304.68 to $304.75. The Reporting Person hereby undertakes, upon request of the Staff of the U.S. Securities Exchange Commission, the Issuer or a security holder of the Issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| December 22, 2022 Filed Dec 27, 2022 17:55 UTC | ABIOMED INC NASD · Entity 121309 | Disposition to issuerPerformance Stock Units · Derivative | 96,265 | Not disclosed Strike: $0.00 | Not disclosed |
DisclosureSEC source: 0001415889-22-013017 · form4-12272022_101240.xml · derivative · entry 12 MINOGUE MICHAEL R · CIK 0001286370 · Director · CHAIRMAN, PRESIDENT, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 96,265 shares Expires not disclosed F6 · kind: Pursuant to the Merger Agreement, each award of restricted stock units with vesting subject to performance-based conditions ("Company PSU Award") outstanding immediately prior to the Effective Time was canceled and converted into the right to receive (i) an amount in cash, without interest, equal to the product of (A) the aggregate number of Issuer Shares underlying such Company PSU Award (assuming (1) the actual level of performance for performance metrics for which the relevant performance period has been completed as of December 22, 2022 (the "Closing Date") and (2) the maximum level of performance under the terms of the applicable award agreement as in effect on the date of the Merger Agreement for performance metrics for which the relevant performance period has not been completed as of the Closing Date (subject, in the case of Company PSU Awards granted to the Chief Executive Officer of the Company, to a maximum level of performance of 200% of the target level of performance) F7 · kind: and (B) the Cash Amount, and (ii) one CVR for each Issuer Share underlying such Company PSU Award (assuming (1) the actual level of performance for performance metrics for which the relevant performance period has been completed as of the Closing Date and (2) the maximum level of performance under the terms of the applicable award agreement as in effect on the date of the Merger Agreement for performance metrics for which the relevant performance period has not been completed as the Closing Date (subject, in the case of Company PSU Awards granted to the Chief Executive Officer of the Company, to a maximum level of performance of 200% of the target level of performance)). F6 · price: Pursuant to the Merger Agreement, each award of restricted stock units with vesting subject to performance-based conditions ("Company PSU Award") outstanding immediately prior to the Effective Time was canceled and converted into the right to receive (i) an amount in cash, without interest, equal to the product of (A) the aggregate number of Issuer Shares underlying such Company PSU Award (assuming (1) the actual level of performance for performance metrics for which the relevant performance period has been completed as of December 22, 2022 (the "Closing Date") and (2) the maximum level of performance under the terms of the applicable award agreement as in effect on the date of the Merger Agreement for performance metrics for which the relevant performance period has not been completed as of the Closing Date (subject, in the case of Company PSU Awards granted to the Chief Executive Officer of the Company, to a maximum level of performance of 200% of the target level of performance) F7 · price: and (B) the Cash Amount, and (ii) one CVR for each Issuer Share underlying such Company PSU Award (assuming (1) the actual level of performance for performance metrics for which the relevant performance period has been completed as of the Closing Date and (2) the maximum level of performance under the terms of the applicable award agreement as in effect on the date of the Merger Agreement for performance metrics for which the relevant performance period has not been completed as the Closing Date (subject, in the case of Company PSU Awards granted to the Chief Executive Officer of the Company, to a maximum level of performance of 200% of the target level of performance)). F6 · derivative.exercise_date: Pursuant to the Merger Agreement, each award of restricted stock units with vesting subject to performance-based conditions ("Company PSU Award") outstanding immediately prior to the Effective Time was canceled and converted into the right to receive (i) an amount in cash, without interest, equal to the product of (A) the aggregate number of Issuer Shares underlying such Company PSU Award (assuming (1) the actual level of performance for performance metrics for which the relevant performance period has been completed as of December 22, 2022 (the "Closing Date") and (2) the maximum level of performance under the terms of the applicable award agreement as in effect on the date of the Merger Agreement for performance metrics for which the relevant performance period has not been completed as of the Closing Date (subject, in the case of Company PSU Awards granted to the Chief Executive Officer of the Company, to a maximum level of performance of 200% of the target level of performance) F7 · derivative.exercise_date: and (B) the Cash Amount, and (ii) one CVR for each Issuer Share underlying such Company PSU Award (assuming (1) the actual level of performance for performance metrics for which the relevant performance period has been completed as of the Closing Date and (2) the maximum level of performance under the terms of the applicable award agreement as in effect on the date of the Merger Agreement for performance metrics for which the relevant performance period has not been completed as the Closing Date (subject, in the case of Company PSU Awards granted to the Chief Executive Officer of the Company, to a maximum level of performance of 200% of the target level of performance)). F6 · derivative.expiration_date: Pursuant to the Merger Agreement, each award of restricted stock units with vesting subject to performance-based conditions ("Company PSU Award") outstanding immediately prior to the Effective Time was canceled and converted into the right to receive (i) an amount in cash, without interest, equal to the product of (A) the aggregate number of Issuer Shares underlying such Company PSU Award (assuming (1) the actual level of performance for performance metrics for which the relevant performance period has been completed as of December 22, 2022 (the "Closing Date") and (2) the maximum level of performance under the terms of the applicable award agreement as in effect on the date of the Merger Agreement for performance metrics for which the relevant performance period has not been completed as of the Closing Date (subject, in the case of Company PSU Awards granted to the Chief Executive Officer of the Company, to a maximum level of performance of 200% of the target level of performance) F7 · derivative.expiration_date: and (B) the Cash Amount, and (ii) one CVR for each Issuer Share underlying such Company PSU Award (assuming (1) the actual level of performance for performance metrics for which the relevant performance period has been completed as of the Closing Date and (2) the maximum level of performance under the terms of the applicable award agreement as in effect on the date of the Merger Agreement for performance metrics for which the relevant performance period has not been completed as the Closing Date (subject, in the case of Company PSU Awards granted to the Chief Executive Officer of the Company, to a maximum level of performance of 200% of the target level of performance)). Read SEC document |
| December 22, 2022 Filed Dec 27, 2022 17:55 UTC | ABIOMED INC NASD · Entity 121309 | GrantPerformance Stock Units · Derivative | 96,265 | Not disclosed Strike: $0.00 | Not disclosed |
DisclosureSEC source: 0001415889-22-013017 · form4-12272022_101240.xml · derivative · entry 11 MINOGUE MICHAEL R · CIK 0001286370 · Director · CHAIRMAN, PRESIDENT, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,265 Underlying: Common Stock · 96,265 shares Expires not disclosed F6 · kind: Pursuant to the Merger Agreement, each award of restricted stock units with vesting subject to performance-based conditions ("Company PSU Award") outstanding immediately prior to the Effective Time was canceled and converted into the right to receive (i) an amount in cash, without interest, equal to the product of (A) the aggregate number of Issuer Shares underlying such Company PSU Award (assuming (1) the actual level of performance for performance metrics for which the relevant performance period has been completed as of December 22, 2022 (the "Closing Date") and (2) the maximum level of performance under the terms of the applicable award agreement as in effect on the date of the Merger Agreement for performance metrics for which the relevant performance period has not been completed as of the Closing Date (subject, in the case of Company PSU Awards granted to the Chief Executive Officer of the Company, to a maximum level of performance of 200% of the target level of performance) F7 · kind: and (B) the Cash Amount, and (ii) one CVR for each Issuer Share underlying such Company PSU Award (assuming (1) the actual level of performance for performance metrics for which the relevant performance period has been completed as of the Closing Date and (2) the maximum level of performance under the terms of the applicable award agreement as in effect on the date of the Merger Agreement for performance metrics for which the relevant performance period has not been completed as the Closing Date (subject, in the case of Company PSU Awards granted to the Chief Executive Officer of the Company, to a maximum level of performance of 200% of the target level of performance)). F6 · price: Pursuant to the Merger Agreement, each award of restricted stock units with vesting subject to performance-based conditions ("Company PSU Award") outstanding immediately prior to the Effective Time was canceled and converted into the right to receive (i) an amount in cash, without interest, equal to the product of (A) the aggregate number of Issuer Shares underlying such Company PSU Award (assuming (1) the actual level of performance for performance metrics for which the relevant performance period has been completed as of December 22, 2022 (the "Closing Date") and (2) the maximum level of performance under the terms of the applicable award agreement as in effect on the date of the Merger Agreement for performance metrics for which the relevant performance period has not been completed as of the Closing Date (subject, in the case of Company PSU Awards granted to the Chief Executive Officer of the Company, to a maximum level of performance of 200% of the target level of performance) F7 · price: and (B) the Cash Amount, and (ii) one CVR for each Issuer Share underlying such Company PSU Award (assuming (1) the actual level of performance for performance metrics for which the relevant performance period has been completed as of the Closing Date and (2) the maximum level of performance under the terms of the applicable award agreement as in effect on the date of the Merger Agreement for performance metrics for which the relevant performance period has not been completed as the Closing Date (subject, in the case of Company PSU Awards granted to the Chief Executive Officer of the Company, to a maximum level of performance of 200% of the target level of performance)). F6 · derivative.exercise_date: Pursuant to the Merger Agreement, each award of restricted stock units with vesting subject to performance-based conditions ("Company PSU Award") outstanding immediately prior to the Effective Time was canceled and converted into the right to receive (i) an amount in cash, without interest, equal to the product of (A) the aggregate number of Issuer Shares underlying such Company PSU Award (assuming (1) the actual level of performance for performance metrics for which the relevant performance period has been completed as of December 22, 2022 (the "Closing Date") and (2) the maximum level of performance under the terms of the applicable award agreement as in effect on the date of the Merger Agreement for performance metrics for which the relevant performance period has not been completed as of the Closing Date (subject, in the case of Company PSU Awards granted to the Chief Executive Officer of the Company, to a maximum level of performance of 200% of the target level of performance) F7 · derivative.exercise_date: and (B) the Cash Amount, and (ii) one CVR for each Issuer Share underlying such Company PSU Award (assuming (1) the actual level of performance for performance metrics for which the relevant performance period has been completed as of the Closing Date and (2) the maximum level of performance under the terms of the applicable award agreement as in effect on the date of the Merger Agreement for performance metrics for which the relevant performance period has not been completed as the Closing Date (subject, in the case of Company PSU Awards granted to the Chief Executive Officer of the Company, to a maximum level of performance of 200% of the target level of performance)). F6 · derivative.expiration_date: Pursuant to the Merger Agreement, each award of restricted stock units with vesting subject to performance-based conditions ("Company PSU Award") outstanding immediately prior to the Effective Time was canceled and converted into the right to receive (i) an amount in cash, without interest, equal to the product of (A) the aggregate number of Issuer Shares underlying such Company PSU Award (assuming (1) the actual level of performance for performance metrics for which the relevant performance period has been completed as of December 22, 2022 (the "Closing Date") and (2) the maximum level of performance under the terms of the applicable award agreement as in effect on the date of the Merger Agreement for performance metrics for which the relevant performance period has not been completed as of the Closing Date (subject, in the case of Company PSU Awards granted to the Chief Executive Officer of the Company, to a maximum level of performance of 200% of the target level of performance) F7 · derivative.expiration_date: and (B) the Cash Amount, and (ii) one CVR for each Issuer Share underlying such Company PSU Award (assuming (1) the actual level of performance for performance metrics for which the relevant performance period has been completed as of the Closing Date and (2) the maximum level of performance under the terms of the applicable award agreement as in effect on the date of the Merger Agreement for performance metrics for which the relevant performance period has not been completed as the Closing Date (subject, in the case of Company PSU Awards granted to the Chief Executive Officer of the Company, to a maximum level of performance of 200% of the target level of performance)). Read SEC document |
| December 22, 2022 Filed Dec 27, 2022 17:55 UTC | ABIOMED INC NASD · Entity 121309 | Disposition to issuerStock Option (Right to Buy) · Derivative | 30,000 | Not disclosed Strike: $283.88 | Not disclosed |
DisclosureSEC source: 0001415889-22-013017 · form4-12272022_101240.xml · derivative · entry 10 MINOGUE MICHAEL R · CIK 0001286370 · Director · CHAIRMAN, PRESIDENT, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 30,000 shares Expires 2031-05-25 F4 · kind: Pursuant to the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each option to purchase Issuer Shares that was outstanding and unexercised immediately prior to the Effective Time was canceled and converted into the right to receive: (1) with respect to each stock option with a per share exercise price less than the Cash Amount (an "In-the-Money Option"), (A) an amount in cash, without interest, equal to the product of (I) the aggregate number of Issuer Shares underlying such In-the-Money Option and (II) the excess, if any, of (x) the Cash Amount over (y) the per share exercise price of such In-the-Money Option and (B) one CVR per Issuer Share underlying such In-the-Money Option; F5 · kind: ; and (2) with respect to each stock option with a per share exercise price that was greater than or equal to the Cash Amount (an "Out-of-the-Money option"), upon each Valuation Point (as defined in the Merger Agreement) occurring after the Effective Time, an amount in cash, without interest, equal to the product of (A) the aggregate number of Issuer Shares underlying such Out-of-the-Money Option and (B) (I) the excess, if any, of (x) the Per Share Value Paid (as defined in the Merger Agreement) as of such Valuation Point over (y) the per share exercise price of such Out-of-the-Money Option, less (II) the amount of all payments previously received with respect to such Out-of-the-Money Option. F4 · price: Pursuant to the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each option to purchase Issuer Shares that was outstanding and unexercised immediately prior to the Effective Time was canceled and converted into the right to receive: (1) with respect to each stock option with a per share exercise price less than the Cash Amount (an "In-the-Money Option"), (A) an amount in cash, without interest, equal to the product of (I) the aggregate number of Issuer Shares underlying such In-the-Money Option and (II) the excess, if any, of (x) the Cash Amount over (y) the per share exercise price of such In-the-Money Option and (B) one CVR per Issuer Share underlying such In-the-Money Option; F5 · price: ; and (2) with respect to each stock option with a per share exercise price that was greater than or equal to the Cash Amount (an "Out-of-the-Money option"), upon each Valuation Point (as defined in the Merger Agreement) occurring after the Effective Time, an amount in cash, without interest, equal to the product of (A) the aggregate number of Issuer Shares underlying such Out-of-the-Money Option and (B) (I) the excess, if any, of (x) the Per Share Value Paid (as defined in the Merger Agreement) as of such Valuation Point over (y) the per share exercise price of such Out-of-the-Money Option, less (II) the amount of all payments previously received with respect to such Out-of-the-Money Option. F4 · derivative.exercise_date: Pursuant to the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each option to purchase Issuer Shares that was outstanding and unexercised immediately prior to the Effective Time was canceled and converted into the right to receive: (1) with respect to each stock option with a per share exercise price less than the Cash Amount (an "In-the-Money Option"), (A) an amount in cash, without interest, equal to the product of (I) the aggregate number of Issuer Shares underlying such In-the-Money Option and (II) the excess, if any, of (x) the Cash Amount over (y) the per share exercise price of such In-the-Money Option and (B) one CVR per Issuer Share underlying such In-the-Money Option; F5 · derivative.exercise_date: ; and (2) with respect to each stock option with a per share exercise price that was greater than or equal to the Cash Amount (an "Out-of-the-Money option"), upon each Valuation Point (as defined in the Merger Agreement) occurring after the Effective Time, an amount in cash, without interest, equal to the product of (A) the aggregate number of Issuer Shares underlying such Out-of-the-Money Option and (B) (I) the excess, if any, of (x) the Per Share Value Paid (as defined in the Merger Agreement) as of such Valuation Point over (y) the per share exercise price of such Out-of-the-Money Option, less (II) the amount of all payments previously received with respect to such Out-of-the-Money Option. Read SEC document |
| December 22, 2022 Filed Dec 27, 2022 17:55 UTC | ABIOMED INC NASD · Entity 121309 | Disposition to issuerStock Option (Right to Buy) · Derivative | 20,898 | Not disclosed Strike: $223.90 | Not disclosed |
DisclosureSEC source: 0001415889-22-013017 · form4-12272022_101240.xml · derivative · entry 9 MINOGUE MICHAEL R · CIK 0001286370 · Director · CHAIRMAN, PRESIDENT, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,898 shares Expires 2030-05-29 F4 · kind: Pursuant to the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each option to purchase Issuer Shares that was outstanding and unexercised immediately prior to the Effective Time was canceled and converted into the right to receive: (1) with respect to each stock option with a per share exercise price less than the Cash Amount (an "In-the-Money Option"), (A) an amount in cash, without interest, equal to the product of (I) the aggregate number of Issuer Shares underlying such In-the-Money Option and (II) the excess, if any, of (x) the Cash Amount over (y) the per share exercise price of such In-the-Money Option and (B) one CVR per Issuer Share underlying such In-the-Money Option; F5 · kind: ; and (2) with respect to each stock option with a per share exercise price that was greater than or equal to the Cash Amount (an "Out-of-the-Money option"), upon each Valuation Point (as defined in the Merger Agreement) occurring after the Effective Time, an amount in cash, without interest, equal to the product of (A) the aggregate number of Issuer Shares underlying such Out-of-the-Money Option and (B) (I) the excess, if any, of (x) the Per Share Value Paid (as defined in the Merger Agreement) as of such Valuation Point over (y) the per share exercise price of such Out-of-the-Money Option, less (II) the amount of all payments previously received with respect to such Out-of-the-Money Option. F4 · price: Pursuant to the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each option to purchase Issuer Shares that was outstanding and unexercised immediately prior to the Effective Time was canceled and converted into the right to receive: (1) with respect to each stock option with a per share exercise price less than the Cash Amount (an "In-the-Money Option"), (A) an amount in cash, without interest, equal to the product of (I) the aggregate number of Issuer Shares underlying such In-the-Money Option and (II) the excess, if any, of (x) the Cash Amount over (y) the per share exercise price of such In-the-Money Option and (B) one CVR per Issuer Share underlying such In-the-Money Option; F5 · price: ; and (2) with respect to each stock option with a per share exercise price that was greater than or equal to the Cash Amount (an "Out-of-the-Money option"), upon each Valuation Point (as defined in the Merger Agreement) occurring after the Effective Time, an amount in cash, without interest, equal to the product of (A) the aggregate number of Issuer Shares underlying such Out-of-the-Money Option and (B) (I) the excess, if any, of (x) the Per Share Value Paid (as defined in the Merger Agreement) as of such Valuation Point over (y) the per share exercise price of such Out-of-the-Money Option, less (II) the amount of all payments previously received with respect to such Out-of-the-Money Option. F4 · derivative.exercise_date: Pursuant to the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each option to purchase Issuer Shares that was outstanding and unexercised immediately prior to the Effective Time was canceled and converted into the right to receive: (1) with respect to each stock option with a per share exercise price less than the Cash Amount (an "In-the-Money Option"), (A) an amount in cash, without interest, equal to the product of (I) the aggregate number of Issuer Shares underlying such In-the-Money Option and (II) the excess, if any, of (x) the Cash Amount over (y) the per share exercise price of such In-the-Money Option and (B) one CVR per Issuer Share underlying such In-the-Money Option; F5 · derivative.exercise_date: ; and (2) with respect to each stock option with a per share exercise price that was greater than or equal to the Cash Amount (an "Out-of-the-Money option"), upon each Valuation Point (as defined in the Merger Agreement) occurring after the Effective Time, an amount in cash, without interest, equal to the product of (A) the aggregate number of Issuer Shares underlying such Out-of-the-Money Option and (B) (I) the excess, if any, of (x) the Per Share Value Paid (as defined in the Merger Agreement) as of such Valuation Point over (y) the per share exercise price of such Out-of-the-Money Option, less (II) the amount of all payments previously received with respect to such Out-of-the-Money Option. Read SEC document |
| December 22, 2022 Filed Dec 27, 2022 17:55 UTC | ABIOMED INC NASD · Entity 121309 | Disposition to issuerStock Option (Right to Buy) · Derivative | 50,000 | Not disclosed Strike: $266.39 | Not disclosed |
DisclosureSEC source: 0001415889-22-013017 · form4-12272022_101240.xml · derivative · entry 8 MINOGUE MICHAEL R · CIK 0001286370 · Director · CHAIRMAN, PRESIDENT, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 50,000 shares Expires 2029-05-30 F4 · kind: Pursuant to the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each option to purchase Issuer Shares that was outstanding and unexercised immediately prior to the Effective Time was canceled and converted into the right to receive: (1) with respect to each stock option with a per share exercise price less than the Cash Amount (an "In-the-Money Option"), (A) an amount in cash, without interest, equal to the product of (I) the aggregate number of Issuer Shares underlying such In-the-Money Option and (II) the excess, if any, of (x) the Cash Amount over (y) the per share exercise price of such In-the-Money Option and (B) one CVR per Issuer Share underlying such In-the-Money Option; F5 · kind: ; and (2) with respect to each stock option with a per share exercise price that was greater than or equal to the Cash Amount (an "Out-of-the-Money option"), upon each Valuation Point (as defined in the Merger Agreement) occurring after the Effective Time, an amount in cash, without interest, equal to the product of (A) the aggregate number of Issuer Shares underlying such Out-of-the-Money Option and (B) (I) the excess, if any, of (x) the Per Share Value Paid (as defined in the Merger Agreement) as of such Valuation Point over (y) the per share exercise price of such Out-of-the-Money Option, less (II) the amount of all payments previously received with respect to such Out-of-the-Money Option. F4 · price: Pursuant to the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each option to purchase Issuer Shares that was outstanding and unexercised immediately prior to the Effective Time was canceled and converted into the right to receive: (1) with respect to each stock option with a per share exercise price less than the Cash Amount (an "In-the-Money Option"), (A) an amount in cash, without interest, equal to the product of (I) the aggregate number of Issuer Shares underlying such In-the-Money Option and (II) the excess, if any, of (x) the Cash Amount over (y) the per share exercise price of such In-the-Money Option and (B) one CVR per Issuer Share underlying such In-the-Money Option; F5 · price: ; and (2) with respect to each stock option with a per share exercise price that was greater than or equal to the Cash Amount (an "Out-of-the-Money option"), upon each Valuation Point (as defined in the Merger Agreement) occurring after the Effective Time, an amount in cash, without interest, equal to the product of (A) the aggregate number of Issuer Shares underlying such Out-of-the-Money Option and (B) (I) the excess, if any, of (x) the Per Share Value Paid (as defined in the Merger Agreement) as of such Valuation Point over (y) the per share exercise price of such Out-of-the-Money Option, less (II) the amount of all payments previously received with respect to such Out-of-the-Money Option. F4 · derivative.exercise_date: Pursuant to the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each option to purchase Issuer Shares that was outstanding and unexercised immediately prior to the Effective Time was canceled and converted into the right to receive: (1) with respect to each stock option with a per share exercise price less than the Cash Amount (an "In-the-Money Option"), (A) an amount in cash, without interest, equal to the product of (I) the aggregate number of Issuer Shares underlying such In-the-Money Option and (II) the excess, if any, of (x) the Cash Amount over (y) the per share exercise price of such In-the-Money Option and (B) one CVR per Issuer Share underlying such In-the-Money Option; F5 · derivative.exercise_date: ; and (2) with respect to each stock option with a per share exercise price that was greater than or equal to the Cash Amount (an "Out-of-the-Money option"), upon each Valuation Point (as defined in the Merger Agreement) occurring after the Effective Time, an amount in cash, without interest, equal to the product of (A) the aggregate number of Issuer Shares underlying such Out-of-the-Money Option and (B) (I) the excess, if any, of (x) the Per Share Value Paid (as defined in the Merger Agreement) as of such Valuation Point over (y) the per share exercise price of such Out-of-the-Money Option, less (II) the amount of all payments previously received with respect to such Out-of-the-Money Option. Read SEC document |
| December 22, 2022 Filed Dec 27, 2022 17:55 UTC | ABIOMED INC NASD · Entity 121309 | Disposition to issuerStock Option (right to buy) · Derivative | 30,000 | Not disclosed Strike: $381.97 | Not disclosed |
DisclosureSEC source: 0001415889-22-013017 · form4-12272022_101240.xml · derivative · entry 7 MINOGUE MICHAEL R · CIK 0001286370 · Director · CHAIRMAN, PRESIDENT, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 30,000 shares Expires 2028-05-16 F4 · kind: Pursuant to the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each option to purchase Issuer Shares that was outstanding and unexercised immediately prior to the Effective Time was canceled and converted into the right to receive: (1) with respect to each stock option with a per share exercise price less than the Cash Amount (an "In-the-Money Option"), (A) an amount in cash, without interest, equal to the product of (I) the aggregate number of Issuer Shares underlying such In-the-Money Option and (II) the excess, if any, of (x) the Cash Amount over (y) the per share exercise price of such In-the-Money Option and (B) one CVR per Issuer Share underlying such In-the-Money Option; F5 · kind: ; and (2) with respect to each stock option with a per share exercise price that was greater than or equal to the Cash Amount (an "Out-of-the-Money option"), upon each Valuation Point (as defined in the Merger Agreement) occurring after the Effective Time, an amount in cash, without interest, equal to the product of (A) the aggregate number of Issuer Shares underlying such Out-of-the-Money Option and (B) (I) the excess, if any, of (x) the Per Share Value Paid (as defined in the Merger Agreement) as of such Valuation Point over (y) the per share exercise price of such Out-of-the-Money Option, less (II) the amount of all payments previously received with respect to such Out-of-the-Money Option. F4 · price: Pursuant to the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each option to purchase Issuer Shares that was outstanding and unexercised immediately prior to the Effective Time was canceled and converted into the right to receive: (1) with respect to each stock option with a per share exercise price less than the Cash Amount (an "In-the-Money Option"), (A) an amount in cash, without interest, equal to the product of (I) the aggregate number of Issuer Shares underlying such In-the-Money Option and (II) the excess, if any, of (x) the Cash Amount over (y) the per share exercise price of such In-the-Money Option and (B) one CVR per Issuer Share underlying such In-the-Money Option; F5 · price: ; and (2) with respect to each stock option with a per share exercise price that was greater than or equal to the Cash Amount (an "Out-of-the-Money option"), upon each Valuation Point (as defined in the Merger Agreement) occurring after the Effective Time, an amount in cash, without interest, equal to the product of (A) the aggregate number of Issuer Shares underlying such Out-of-the-Money Option and (B) (I) the excess, if any, of (x) the Per Share Value Paid (as defined in the Merger Agreement) as of such Valuation Point over (y) the per share exercise price of such Out-of-the-Money Option, less (II) the amount of all payments previously received with respect to such Out-of-the-Money Option. F4 · derivative.exercise_date: Pursuant to the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each option to purchase Issuer Shares that was outstanding and unexercised immediately prior to the Effective Time was canceled and converted into the right to receive: (1) with respect to each stock option with a per share exercise price less than the Cash Amount (an "In-the-Money Option"), (A) an amount in cash, without interest, equal to the product of (I) the aggregate number of Issuer Shares underlying such In-the-Money Option and (II) the excess, if any, of (x) the Cash Amount over (y) the per share exercise price of such In-the-Money Option and (B) one CVR per Issuer Share underlying such In-the-Money Option; F5 · derivative.exercise_date: ; and (2) with respect to each stock option with a per share exercise price that was greater than or equal to the Cash Amount (an "Out-of-the-Money option"), upon each Valuation Point (as defined in the Merger Agreement) occurring after the Effective Time, an amount in cash, without interest, equal to the product of (A) the aggregate number of Issuer Shares underlying such Out-of-the-Money Option and (B) (I) the excess, if any, of (x) the Per Share Value Paid (as defined in the Merger Agreement) as of such Valuation Point over (y) the per share exercise price of such Out-of-the-Money Option, less (II) the amount of all payments previously received with respect to such Out-of-the-Money Option. Read SEC document |
| December 22, 2022 Filed Dec 27, 2022 17:55 UTC | ABIOMED INC NASD · Entity 121309 | Disposition to issuerStock Option (right to buy) · Derivative | 33,000 | Not disclosed Strike: $134.51 | Not disclosed |
DisclosureSEC source: 0001415889-22-013017 · form4-12272022_101240.xml · derivative · entry 6 MINOGUE MICHAEL R · CIK 0001286370 · Director · CHAIRMAN, PRESIDENT, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 33,000 shares Expires 2027-05-15 F4 · kind: Pursuant to the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each option to purchase Issuer Shares that was outstanding and unexercised immediately prior to the Effective Time was canceled and converted into the right to receive: (1) with respect to each stock option with a per share exercise price less than the Cash Amount (an "In-the-Money Option"), (A) an amount in cash, without interest, equal to the product of (I) the aggregate number of Issuer Shares underlying such In-the-Money Option and (II) the excess, if any, of (x) the Cash Amount over (y) the per share exercise price of such In-the-Money Option and (B) one CVR per Issuer Share underlying such In-the-Money Option; F5 · kind: ; and (2) with respect to each stock option with a per share exercise price that was greater than or equal to the Cash Amount (an "Out-of-the-Money option"), upon each Valuation Point (as defined in the Merger Agreement) occurring after the Effective Time, an amount in cash, without interest, equal to the product of (A) the aggregate number of Issuer Shares underlying such Out-of-the-Money Option and (B) (I) the excess, if any, of (x) the Per Share Value Paid (as defined in the Merger Agreement) as of such Valuation Point over (y) the per share exercise price of such Out-of-the-Money Option, less (II) the amount of all payments previously received with respect to such Out-of-the-Money Option. F4 · price: Pursuant to the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each option to purchase Issuer Shares that was outstanding and unexercised immediately prior to the Effective Time was canceled and converted into the right to receive: (1) with respect to each stock option with a per share exercise price less than the Cash Amount (an "In-the-Money Option"), (A) an amount in cash, without interest, equal to the product of (I) the aggregate number of Issuer Shares underlying such In-the-Money Option and (II) the excess, if any, of (x) the Cash Amount over (y) the per share exercise price of such In-the-Money Option and (B) one CVR per Issuer Share underlying such In-the-Money Option; F5 · price: ; and (2) with respect to each stock option with a per share exercise price that was greater than or equal to the Cash Amount (an "Out-of-the-Money option"), upon each Valuation Point (as defined in the Merger Agreement) occurring after the Effective Time, an amount in cash, without interest, equal to the product of (A) the aggregate number of Issuer Shares underlying such Out-of-the-Money Option and (B) (I) the excess, if any, of (x) the Per Share Value Paid (as defined in the Merger Agreement) as of such Valuation Point over (y) the per share exercise price of such Out-of-the-Money Option, less (II) the amount of all payments previously received with respect to such Out-of-the-Money Option. F4 · derivative.exercise_date: Pursuant to the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each option to purchase Issuer Shares that was outstanding and unexercised immediately prior to the Effective Time was canceled and converted into the right to receive: (1) with respect to each stock option with a per share exercise price less than the Cash Amount (an "In-the-Money Option"), (A) an amount in cash, without interest, equal to the product of (I) the aggregate number of Issuer Shares underlying such In-the-Money Option and (II) the excess, if any, of (x) the Cash Amount over (y) the per share exercise price of such In-the-Money Option and (B) one CVR per Issuer Share underlying such In-the-Money Option; F5 · derivative.exercise_date: ; and (2) with respect to each stock option with a per share exercise price that was greater than or equal to the Cash Amount (an "Out-of-the-Money option"), upon each Valuation Point (as defined in the Merger Agreement) occurring after the Effective Time, an amount in cash, without interest, equal to the product of (A) the aggregate number of Issuer Shares underlying such Out-of-the-Money Option and (B) (I) the excess, if any, of (x) the Per Share Value Paid (as defined in the Merger Agreement) as of such Valuation Point over (y) the per share exercise price of such Out-of-the-Money Option, less (II) the amount of all payments previously received with respect to such Out-of-the-Money Option. Read SEC document |
| December 22, 2022 Filed Dec 27, 2022 17:55 UTC | ABIOMED INC NASD · Entity 121309 | Disposition to issuerStock Option (right to buy) · Derivative | 30,500 | Not disclosed Strike: $99.62 | Not disclosed |
DisclosureSEC source: 0001415889-22-013017 · form4-12272022_101240.xml · derivative · entry 5 MINOGUE MICHAEL R · CIK 0001286370 · Director · CHAIRMAN, PRESIDENT, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 30,500 shares Expires 2026-05-24 F4 · kind: Pursuant to the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each option to purchase Issuer Shares that was outstanding and unexercised immediately prior to the Effective Time was canceled and converted into the right to receive: (1) with respect to each stock option with a per share exercise price less than the Cash Amount (an "In-the-Money Option"), (A) an amount in cash, without interest, equal to the product of (I) the aggregate number of Issuer Shares underlying such In-the-Money Option and (II) the excess, if any, of (x) the Cash Amount over (y) the per share exercise price of such In-the-Money Option and (B) one CVR per Issuer Share underlying such In-the-Money Option; F5 · kind: ; and (2) with respect to each stock option with a per share exercise price that was greater than or equal to the Cash Amount (an "Out-of-the-Money option"), upon each Valuation Point (as defined in the Merger Agreement) occurring after the Effective Time, an amount in cash, without interest, equal to the product of (A) the aggregate number of Issuer Shares underlying such Out-of-the-Money Option and (B) (I) the excess, if any, of (x) the Per Share Value Paid (as defined in the Merger Agreement) as of such Valuation Point over (y) the per share exercise price of such Out-of-the-Money Option, less (II) the amount of all payments previously received with respect to such Out-of-the-Money Option. F4 · price: Pursuant to the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each option to purchase Issuer Shares that was outstanding and unexercised immediately prior to the Effective Time was canceled and converted into the right to receive: (1) with respect to each stock option with a per share exercise price less than the Cash Amount (an "In-the-Money Option"), (A) an amount in cash, without interest, equal to the product of (I) the aggregate number of Issuer Shares underlying such In-the-Money Option and (II) the excess, if any, of (x) the Cash Amount over (y) the per share exercise price of such In-the-Money Option and (B) one CVR per Issuer Share underlying such In-the-Money Option; F5 · price: ; and (2) with respect to each stock option with a per share exercise price that was greater than or equal to the Cash Amount (an "Out-of-the-Money option"), upon each Valuation Point (as defined in the Merger Agreement) occurring after the Effective Time, an amount in cash, without interest, equal to the product of (A) the aggregate number of Issuer Shares underlying such Out-of-the-Money Option and (B) (I) the excess, if any, of (x) the Per Share Value Paid (as defined in the Merger Agreement) as of such Valuation Point over (y) the per share exercise price of such Out-of-the-Money Option, less (II) the amount of all payments previously received with respect to such Out-of-the-Money Option. F4 · derivative.exercise_date: Pursuant to the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each option to purchase Issuer Shares that was outstanding and unexercised immediately prior to the Effective Time was canceled and converted into the right to receive: (1) with respect to each stock option with a per share exercise price less than the Cash Amount (an "In-the-Money Option"), (A) an amount in cash, without interest, equal to the product of (I) the aggregate number of Issuer Shares underlying such In-the-Money Option and (II) the excess, if any, of (x) the Cash Amount over (y) the per share exercise price of such In-the-Money Option and (B) one CVR per Issuer Share underlying such In-the-Money Option; F5 · derivative.exercise_date: ; and (2) with respect to each stock option with a per share exercise price that was greater than or equal to the Cash Amount (an "Out-of-the-Money option"), upon each Valuation Point (as defined in the Merger Agreement) occurring after the Effective Time, an amount in cash, without interest, equal to the product of (A) the aggregate number of Issuer Shares underlying such Out-of-the-Money Option and (B) (I) the excess, if any, of (x) the Per Share Value Paid (as defined in the Merger Agreement) as of such Valuation Point over (y) the per share exercise price of such Out-of-the-Money Option, less (II) the amount of all payments previously received with respect to such Out-of-the-Money Option. Read SEC document |
| December 22, 2022 Filed Dec 27, 2022 17:55 UTC | ABIOMED INC NASD · Entity 121309 | Disposition to issuerStock Option (right to buy) · Derivative | 35,000 | Not disclosed Strike: $66.25 | Not disclosed |
DisclosureSEC source: 0001415889-22-013017 · form4-12272022_101240.xml · derivative · entry 4 MINOGUE MICHAEL R · CIK 0001286370 · Director · CHAIRMAN, PRESIDENT, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 35,000 shares Expires 2025-05-13 F4 · kind: Pursuant to the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each option to purchase Issuer Shares that was outstanding and unexercised immediately prior to the Effective Time was canceled and converted into the right to receive: (1) with respect to each stock option with a per share exercise price less than the Cash Amount (an "In-the-Money Option"), (A) an amount in cash, without interest, equal to the product of (I) the aggregate number of Issuer Shares underlying such In-the-Money Option and (II) the excess, if any, of (x) the Cash Amount over (y) the per share exercise price of such In-the-Money Option and (B) one CVR per Issuer Share underlying such In-the-Money Option; F5 · kind: ; and (2) with respect to each stock option with a per share exercise price that was greater than or equal to the Cash Amount (an "Out-of-the-Money option"), upon each Valuation Point (as defined in the Merger Agreement) occurring after the Effective Time, an amount in cash, without interest, equal to the product of (A) the aggregate number of Issuer Shares underlying such Out-of-the-Money Option and (B) (I) the excess, if any, of (x) the Per Share Value Paid (as defined in the Merger Agreement) as of such Valuation Point over (y) the per share exercise price of such Out-of-the-Money Option, less (II) the amount of all payments previously received with respect to such Out-of-the-Money Option. F4 · price: Pursuant to the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each option to purchase Issuer Shares that was outstanding and unexercised immediately prior to the Effective Time was canceled and converted into the right to receive: (1) with respect to each stock option with a per share exercise price less than the Cash Amount (an "In-the-Money Option"), (A) an amount in cash, without interest, equal to the product of (I) the aggregate number of Issuer Shares underlying such In-the-Money Option and (II) the excess, if any, of (x) the Cash Amount over (y) the per share exercise price of such In-the-Money Option and (B) one CVR per Issuer Share underlying such In-the-Money Option; F5 · price: ; and (2) with respect to each stock option with a per share exercise price that was greater than or equal to the Cash Amount (an "Out-of-the-Money option"), upon each Valuation Point (as defined in the Merger Agreement) occurring after the Effective Time, an amount in cash, without interest, equal to the product of (A) the aggregate number of Issuer Shares underlying such Out-of-the-Money Option and (B) (I) the excess, if any, of (x) the Per Share Value Paid (as defined in the Merger Agreement) as of such Valuation Point over (y) the per share exercise price of such Out-of-the-Money Option, less (II) the amount of all payments previously received with respect to such Out-of-the-Money Option. F4 · derivative.exercise_date: Pursuant to the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each option to purchase Issuer Shares that was outstanding and unexercised immediately prior to the Effective Time was canceled and converted into the right to receive: (1) with respect to each stock option with a per share exercise price less than the Cash Amount (an "In-the-Money Option"), (A) an amount in cash, without interest, equal to the product of (I) the aggregate number of Issuer Shares underlying such In-the-Money Option and (II) the excess, if any, of (x) the Cash Amount over (y) the per share exercise price of such In-the-Money Option and (B) one CVR per Issuer Share underlying such In-the-Money Option; F5 · derivative.exercise_date: ; and (2) with respect to each stock option with a per share exercise price that was greater than or equal to the Cash Amount (an "Out-of-the-Money option"), upon each Valuation Point (as defined in the Merger Agreement) occurring after the Effective Time, an amount in cash, without interest, equal to the product of (A) the aggregate number of Issuer Shares underlying such Out-of-the-Money Option and (B) (I) the excess, if any, of (x) the Per Share Value Paid (as defined in the Merger Agreement) as of such Valuation Point over (y) the per share exercise price of such Out-of-the-Money Option, less (II) the amount of all payments previously received with respect to such Out-of-the-Money Option. Read SEC document |
| December 22, 2022 Filed Dec 27, 2022 17:55 UTC | ABIOMED INC NASD · Entity 121309 | Disposition to issuerStock Option (right to buy) · Derivative | 85,000 | Not disclosed Strike: $21.55 | Not disclosed |
DisclosureSEC source: 0001415889-22-013017 · form4-12272022_101240.xml · derivative · entry 3 MINOGUE MICHAEL R · CIK 0001286370 · Director · CHAIRMAN, PRESIDENT, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 85,000 shares Expires 2024-05-14 F4 · kind: Pursuant to the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each option to purchase Issuer Shares that was outstanding and unexercised immediately prior to the Effective Time was canceled and converted into the right to receive: (1) with respect to each stock option with a per share exercise price less than the Cash Amount (an "In-the-Money Option"), (A) an amount in cash, without interest, equal to the product of (I) the aggregate number of Issuer Shares underlying such In-the-Money Option and (II) the excess, if any, of (x) the Cash Amount over (y) the per share exercise price of such In-the-Money Option and (B) one CVR per Issuer Share underlying such In-the-Money Option; F5 · kind: ; and (2) with respect to each stock option with a per share exercise price that was greater than or equal to the Cash Amount (an "Out-of-the-Money option"), upon each Valuation Point (as defined in the Merger Agreement) occurring after the Effective Time, an amount in cash, without interest, equal to the product of (A) the aggregate number of Issuer Shares underlying such Out-of-the-Money Option and (B) (I) the excess, if any, of (x) the Per Share Value Paid (as defined in the Merger Agreement) as of such Valuation Point over (y) the per share exercise price of such Out-of-the-Money Option, less (II) the amount of all payments previously received with respect to such Out-of-the-Money Option. F4 · price: Pursuant to the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each option to purchase Issuer Shares that was outstanding and unexercised immediately prior to the Effective Time was canceled and converted into the right to receive: (1) with respect to each stock option with a per share exercise price less than the Cash Amount (an "In-the-Money Option"), (A) an amount in cash, without interest, equal to the product of (I) the aggregate number of Issuer Shares underlying such In-the-Money Option and (II) the excess, if any, of (x) the Cash Amount over (y) the per share exercise price of such In-the-Money Option and (B) one CVR per Issuer Share underlying such In-the-Money Option; F5 · price: ; and (2) with respect to each stock option with a per share exercise price that was greater than or equal to the Cash Amount (an "Out-of-the-Money option"), upon each Valuation Point (as defined in the Merger Agreement) occurring after the Effective Time, an amount in cash, without interest, equal to the product of (A) the aggregate number of Issuer Shares underlying such Out-of-the-Money Option and (B) (I) the excess, if any, of (x) the Per Share Value Paid (as defined in the Merger Agreement) as of such Valuation Point over (y) the per share exercise price of such Out-of-the-Money Option, less (II) the amount of all payments previously received with respect to such Out-of-the-Money Option. F4 · derivative.exercise_date: Pursuant to the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each option to purchase Issuer Shares that was outstanding and unexercised immediately prior to the Effective Time was canceled and converted into the right to receive: (1) with respect to each stock option with a per share exercise price less than the Cash Amount (an "In-the-Money Option"), (A) an amount in cash, without interest, equal to the product of (I) the aggregate number of Issuer Shares underlying such In-the-Money Option and (II) the excess, if any, of (x) the Cash Amount over (y) the per share exercise price of such In-the-Money Option and (B) one CVR per Issuer Share underlying such In-the-Money Option; F5 · derivative.exercise_date: ; and (2) with respect to each stock option with a per share exercise price that was greater than or equal to the Cash Amount (an "Out-of-the-Money option"), upon each Valuation Point (as defined in the Merger Agreement) occurring after the Effective Time, an amount in cash, without interest, equal to the product of (A) the aggregate number of Issuer Shares underlying such Out-of-the-Money Option and (B) (I) the excess, if any, of (x) the Per Share Value Paid (as defined in the Merger Agreement) as of such Valuation Point over (y) the per share exercise price of such Out-of-the-Money Option, less (II) the amount of all payments previously received with respect to such Out-of-the-Money Option. Read SEC document |
| December 22, 2022 Filed Dec 27, 2022 17:55 UTC | ABIOMED INC NASD · Entity 121309 | Disposition to issuerCommon Stock $.01 par value | 243,962 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-22-013017 · form4-12272022_101240.xml · nonDerivative · entry 2 MINOGUE MICHAEL R · CIK 0001286370 · Director · CHAIRMAN, PRESIDENT, CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 0 F1 · kind: Disposed in connection with transactions contemplated by the Agreement and Plan of Merger, dated as of October 31, 2022 (the "Merger Agreement"), by and among the Issuer, Johnson & Johnson ("Parent") and Athos Merger Sub, Inc. ("Merger Sub"), pursuant to which, on December 22, 2022, Merger Sub was merged with and into the Issuer (the "Merger"), with the Issuer surviving the Merger as a wholly owned subsidiary of Parent. As a result of the Merger, each outstanding share of common stock, par value $0.01 per share, of the Issuer (each, an "Issuer Share") was automatically converted into the right to receive (i) an amount in cash equal to $380.00 (the "Cash Amount"), plus (ii) one non-tradeable contingent value right (the "CVR"), representing the right to receive contingent payments of up to $35.00 per Issuer Share, payable upon the achievement of certain specified milestones set out in the Contingent Value Rights Agreement. F3 · shares: This number reflects unvested Company RSU Awards and shares of common stock. The Form 4 filed on December 20, 2022 for Michael Minogue inadvertently omitted unvested Company RSU Awards from the balance of non-derivative securities beneficially owned by the reporting person. F1 · price: Disposed in connection with transactions contemplated by the Agreement and Plan of Merger, dated as of October 31, 2022 (the "Merger Agreement"), by and among the Issuer, Johnson & Johnson ("Parent") and Athos Merger Sub, Inc. ("Merger Sub"), pursuant to which, on December 22, 2022, Merger Sub was merged with and into the Issuer (the "Merger"), with the Issuer surviving the Merger as a wholly owned subsidiary of Parent. As a result of the Merger, each outstanding share of common stock, par value $0.01 per share, of the Issuer (each, an "Issuer Share") was automatically converted into the right to receive (i) an amount in cash equal to $380.00 (the "Cash Amount"), plus (ii) one non-tradeable contingent value right (the "CVR"), representing the right to receive contingent payments of up to $35.00 per Issuer Share, payable upon the achievement of certain specified milestones set out in the Contingent Value Rights Agreement. Read SEC document |
| December 22, 2022 Filed Dec 27, 2022 17:55 UTC | ABIOMED INC NASD · Entity 121309 | Disposition to issuerCommon Stock $.01 par value | 166,670 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-22-013017 · form4-12272022_101240.xml · nonDerivative · entry 1 MINOGUE MICHAEL R · CIK 0001286370 · Director · CHAIRMAN, PRESIDENT, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: Disposed in connection with transactions contemplated by the Agreement and Plan of Merger, dated as of October 31, 2022 (the "Merger Agreement"), by and among the Issuer, Johnson & Johnson ("Parent") and Athos Merger Sub, Inc. ("Merger Sub"), pursuant to which, on December 22, 2022, Merger Sub was merged with and into the Issuer (the "Merger"), with the Issuer surviving the Merger as a wholly owned subsidiary of Parent. As a result of the Merger, each outstanding share of common stock, par value $0.01 per share, of the Issuer (each, an "Issuer Share") was automatically converted into the right to receive (i) an amount in cash equal to $380.00 (the "Cash Amount"), plus (ii) one non-tradeable contingent value right (the "CVR"), representing the right to receive contingent payments of up to $35.00 per Issuer Share, payable upon the achievement of certain specified milestones set out in the Contingent Value Rights Agreement. F2 · kind: Pursuant to the Merger Agreement, each award of restricted stock units of the Issuer, excluding any award of restricted stock units with vesting subject to performance-based conditions ("Company RSU Award"), outstanding as of immediately prior to the Effective Time was canceled and converted into the right to receive (i) an amount in cash, without interest, equal to the product of (A) the aggregate number of Issuer Shares underlying such Company RSU Award and (B) the Cash Amount and (ii) one CVR per Issuer Share. F3 · shares: This number reflects unvested Company RSU Awards and shares of common stock. The Form 4 filed on December 20, 2022 for Michael Minogue inadvertently omitted unvested Company RSU Awards from the balance of non-derivative securities beneficially owned by the reporting person. F1 · price: Disposed in connection with transactions contemplated by the Agreement and Plan of Merger, dated as of October 31, 2022 (the "Merger Agreement"), by and among the Issuer, Johnson & Johnson ("Parent") and Athos Merger Sub, Inc. ("Merger Sub"), pursuant to which, on December 22, 2022, Merger Sub was merged with and into the Issuer (the "Merger"), with the Issuer surviving the Merger as a wholly owned subsidiary of Parent. As a result of the Merger, each outstanding share of common stock, par value $0.01 per share, of the Issuer (each, an "Issuer Share") was automatically converted into the right to receive (i) an amount in cash equal to $380.00 (the "Cash Amount"), plus (ii) one non-tradeable contingent value right (the "CVR"), representing the right to receive contingent payments of up to $35.00 per Issuer Share, payable upon the achievement of certain specified milestones set out in the Contingent Value Rights Agreement. F2 · price: Pursuant to the Merger Agreement, each award of restricted stock units of the Issuer, excluding any award of restricted stock units with vesting subject to performance-based conditions ("Company RSU Award"), outstanding as of immediately prior to the Effective Time was canceled and converted into the right to receive (i) an amount in cash, without interest, equal to the product of (A) the aggregate number of Issuer Shares underlying such Company RSU Award and (B) the Cash Amount and (ii) one CVR per Issuer Share. Read SEC document |
| December 16, 2022 Filed Dec 20, 2022 16:02 UTC | ABIOMED INC NASD · Entity 121309 | GrantCommon Stock $.01 par value | 1 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-22-012840 · form4-12202022_091241.xml · nonDerivative · entry 1 MINOGUE MICHAEL R · CIK 0001286370 · Director · CHAIRMAN, PRESIDENT, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 136,086 F1 · kind: These shares of common stock were acquired by the reporting person through participation in the ABIOMED, Inc. Employee Stock Purchase Plan, qualified under Section 423 of the Internal Revenue Code, and the transaction was exempt under Rule 16b-3(c) F1 · shares: These shares of common stock were acquired by the reporting person through participation in the ABIOMED, Inc. Employee Stock Purchase Plan, qualified under Section 423 of the Internal Revenue Code, and the transaction was exempt under Rule 16b-3(c) Read SEC document |
| November 05, 2022 Filed Nov 8, 2022 16:30 UTC | ABIOMED INC NASD · Entity 121309 | Tax withholdingCommon Stock $.01 par value | 5,164 | $373.99 | $1,931,284.36 |
DisclosureSEC source: 0001415889-22-011180 · form4-11082022_091109.xml · nonDerivative · entry 1 MINOGUE MICHAEL R · CIK 0001286370 · Director · CHAIRMAN, PRESIDENT, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 248,146 F1 · kind: Transaction represents shares of common stock withheld solely for the payment of withholding tax liability associated with the vesting of awards of restricted stock units in accordance with the time periods set forth in such awards. F1 · shares: Transaction represents shares of common stock withheld solely for the payment of withholding tax liability associated with the vesting of awards of restricted stock units in accordance with the time periods set forth in such awards. Read SEC document |
| September 30, 2022 Filed Oct 4, 2022 16:13 UTC | ABIOMED INC NASD · Entity 121309 | GrantCommon Stock $.01 par value | 32 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-22-010220 · form4-10042022_011027.xml · nonDerivative · entry 1 MINOGUE MICHAEL R · CIK 0001286370 · Director · CHAIRMAN, PRESIDENT, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 253,310 F1 · kind: These shares of common stock were acquired by the reporting person through participation in the ABIOMED, Inc. Employee Stock Purchase Plan, qualified under Section 423 of the Internal Revenue Code, and the transaction was exempt under Rule 16b-3(c) F1 · shares: These shares of common stock were acquired by the reporting person through participation in the ABIOMED, Inc. Employee Stock Purchase Plan, qualified under Section 423 of the Internal Revenue Code, and the transaction was exempt under Rule 16b-3(c) Read SEC document |
| June 15, 2022 Filed Jul 6, 2022 20:14 UTC | INSULET CORP PODD · Entity 3516 | GiftCommon Stock | 808 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-018928 · form4.xml · nonDerivative · entry 2 MINOGUE MICHAEL R · CIK 0001286370 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 8,921 F1 · shares: This transaction represents the transfer of common stock by bona fide gift from the reporting person to a trust held for the benefit of the reporting person's spouse. The reporting person's spouse is a trustee of the trust. Read SEC document |
| June 15, 2022 Filed Jul 6, 2022 20:14 UTC | INSULET CORP PODD · Entity 3516 | GiftCommon Stock | 808 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-018928 · form4.xml · nonDerivative · entry 1 MINOGUE MICHAEL R · CIK 0001286370 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,009 F1 · shares: This transaction represents the transfer of common stock by bona fide gift from the reporting person to a trust held for the benefit of the reporting person's spouse. The reporting person's spouse is a trustee of the trust. Read SEC document |
| May 29, 2022 Filed May 31, 2022 17:26 UTC | ABIOMED INC NASD · Entity 121309 | Tax withholdingCommon Stock $.01 par value | 1,563 | $266.34 | $416,289.42 |
DisclosureSEC source: 0001415889-22-005926 · form4-05312022_020547.xml · nonDerivative · entry 4 MINOGUE MICHAEL R · CIK 0001286370 · Director · CHAIRMAN, PRESIDENT, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 253,278 F3 · kind: Transaction represents shares of common stock withheld solely for the payment of withholding tax liability associated with the vesting of awards of restricted stock units in accordance with the time periods set forth in such awards. F3 · shares: Transaction represents shares of common stock withheld solely for the payment of withholding tax liability associated with the vesting of awards of restricted stock units in accordance with the time periods set forth in such awards. Read SEC document |
| May 29, 2022 Filed May 31, 2022 17:26 UTC | ABIOMED INC NASD · Entity 121309 | Tax withholdingCommon Stock $.01 par value | 3,906 | $266.34 | $1,040,324.04 |
DisclosureSEC source: 0001415889-22-005926 · form4-05312022_020547.xml · nonDerivative · entry 3 MINOGUE MICHAEL R · CIK 0001286370 · Director · CHAIRMAN, PRESIDENT, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 254,841 F3 · kind: Transaction represents shares of common stock withheld solely for the payment of withholding tax liability associated with the vesting of awards of restricted stock units in accordance with the time periods set forth in such awards. F3 · shares: Transaction represents shares of common stock withheld solely for the payment of withholding tax liability associated with the vesting of awards of restricted stock units in accordance with the time periods set forth in such awards. Read SEC document |
| May 29, 2022 Filed May 31, 2022 17:26 UTC | ABIOMED INC NASD · Entity 121309 | GrantCommon Stock $.01 par value | 8,806 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-22-005926 · form4-05312022_020547.xml · nonDerivative · entry 2 MINOGUE MICHAEL R · CIK 0001286370 · Director · CHAIRMAN, PRESIDENT, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 258,747 F2 · kind: Represents shares of common stock underlying performance-based awards of restricted stock units granted to this reporting person on May 29, 2020. One hundred percent of these restricted stock units vested on May 29, 2022 (into an equal number of shares of common stock) based on the issuer's achievement of a certain performance milestone. F2 · shares: Represents shares of common stock underlying performance-based awards of restricted stock units granted to this reporting person on May 29, 2020. One hundred percent of these restricted stock units vested on May 29, 2022 (into an equal number of shares of common stock) based on the issuer's achievement of a certain performance milestone. Read SEC document |
| May 26, 2022 Filed May 31, 2022 17:26 UTC | ABIOMED INC NASD · Entity 121309 | GrantCommon Stock $.01 par value | 21,393 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-22-005926 · form4-05312022_020547.xml · nonDerivative · entry 1 MINOGUE MICHAEL R · CIK 0001286370 · Director · CHAIRMAN, PRESIDENT, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 249,941 F1 · kind: Consists of restricted stock units granted to the reporting person. One third of the restricted stock units will vest and the underlying shares will be issued to the reporting person on each of May 26, 2023, May 26, 2024 and May 26, 2025, so long as the reporting person continues to be employed by the issuer on the vesting dates. F1 · shares: Consists of restricted stock units granted to the reporting person. One third of the restricted stock units will vest and the underlying shares will be issued to the reporting person on each of May 26, 2023, May 26, 2024 and May 26, 2025, so long as the reporting person continues to be employed by the issuer on the vesting dates. Read SEC document |
| May 25, 2022 Filed May 27, 2022 16:05 UTC | ABIOMED INC NASD · Entity 121309 | Tax withholdingCommon Stock $.01 par value | 1,258 | $249.19 | $313,481.02 |
DisclosureSEC source: 0001415889-22-005792 · form4-05272022_010503.xml · nonDerivative · entry 1 MINOGUE MICHAEL R · CIK 0001286370 · Director · CHAIRMAN, PRESIDENT, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 228,548 F1 · kind: Transaction represents shares of common stock withheld solely for the payment of withholding tax liability associated with the vesting of awards of restricted stock units in accordance with the time periods set forth in such awards. F1 · shares: Transaction represents shares of common stock withheld solely for the payment of withholding tax liability associated with the vesting of awards of restricted stock units in accordance with the time periods set forth in such awards. Read SEC document |
| May 24, 2022 Filed May 26, 2022 20:10 UTC | INSULET CORP PODD · Entity 3516 | GrantCommon Stock | 1,009 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-015765 · form4.xml · nonDerivative · entry 3 MINOGUE MICHAEL R · CIK 0001286370 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,817 F2 · shares: Annual equity award in the form of restricted stock units ("RSUs"). These RSUs vest in full on April 30, 2023 and are settled in shares of common stock on a one-for-one basis. Read SEC document |
| March 31, 2022 Filed Apr 4, 2022 17:14 UTC | ABIOMED INC NASD · Entity 121309 | GrantCommon Stock $.01 par value | 43 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-22-003746 · form4-04042022_020436.xml · nonDerivative · entry 1 MINOGUE MICHAEL R · CIK 0001286370 · Director · CHAIRMAN, PRESIDENT, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 229,806 F1 · kind: These shares of common stock were acquired by the reporting person through participation in the ABIOMED, Inc. Employee Stock Purchase Plan, qualified under Section 423 of the Internal Revenue Code, and the transaction was exempt under Rule 16b-3(c). F1 · shares: These shares of common stock were acquired by the reporting person through participation in the ABIOMED, Inc. Employee Stock Purchase Plan, qualified under Section 423 of the Internal Revenue Code, and the transaction was exempt under Rule 16b-3(c). Read SEC document |
| March 15, 2022 Filed May 26, 2022 20:10 UTC | INSULET CORP PODD · Entity 3516 | GiftCommon Stock | 3,549 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-015765 · form4.xml · nonDerivative · entry 2 MINOGUE MICHAEL R · CIK 0001286370 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 8,113 F1 · shares: This transaction represents the transfer of common stock by bona fide gift from the reporting person to a trust held for the benefit of the reporting person's spouse. The reporting person's spouse is a trustee of the trust. Read SEC document |
| March 15, 2022 Filed May 26, 2022 20:10 UTC | INSULET CORP PODD · Entity 3516 | GiftCommon Stock | 3,549 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-015765 · form4.xml · nonDerivative · entry 1 MINOGUE MICHAEL R · CIK 0001286370 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 808 F1 · shares: This transaction represents the transfer of common stock by bona fide gift from the reporting person to a trust held for the benefit of the reporting person's spouse. The reporting person's spouse is a trustee of the trust. Read SEC document |
| November 03, 2021 Filed Nov 5, 2021 16:30 UTC | ABIOMED INC ABMD · Entity 121309 | Tax withholdingCommon Stock $.01 par value | 5,158 | $349.76 | $1,804,062.08 |
DisclosureSEC source: 0001179110-21-009903 · edgar.xml · nonDerivative · entry 2 MINOGUE MICHAEL R · CIK 0001286370 · Director · Chairman, President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 229,763 F5 · kind: Transaction represents shares of common stock withheld solely for the payment of withholding tax liability associated with the vesting of awards of restricted stock units in accordance with the time periods set forth in such awards. F5 · shares: Transaction represents shares of common stock withheld solely for the payment of withholding tax liability associated with the vesting of awards of restricted stock units in accordance with the time periods set forth in such awards. Read SEC document |
| November 03, 2021 Filed Nov 5, 2021 16:30 UTC | ABIOMED INC ABMD · Entity 121309 | GrantCommon Stock $.01 par value | 23,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-21-009903 · edgar.xml · nonDerivative · entry 1 MINOGUE MICHAEL R · CIK 0001286370 · Director · Chairman, President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 234,921 F4 · kind: Represents shares of common stock underlying performance-based awards of restricted stock units granted to this reporting person on November 5, 2020. One half of these restricted stock units vested on November 3, 2021 (into an equal number of shares of common stock) based on the issuer's achievement of a certain performance milestone with the remaining vesting on the second anniversary of the date of grant as long as the reporting person continues to be employed by the issuer on the vesting dates. F4 · shares: Represents shares of common stock underlying performance-based awards of restricted stock units granted to this reporting person on November 5, 2020. One half of these restricted stock units vested on November 3, 2021 (into an equal number of shares of common stock) based on the issuer's achievement of a certain performance milestone with the remaining vesting on the second anniversary of the date of grant as long as the reporting person continues to be employed by the issuer on the vesting dates. Read SEC document |
| September 30, 2021 Filed Oct 4, 2021 17:19 UTC | ABIOMED INC ABMD · Entity 121309 | GrantCommon Stock $.01 par value | 36 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-21-009164 · edgar.xml · nonDerivative · entry 1 MINOGUE MICHAEL R · CIK 0001286370 · Director · Chairman, President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 211,671 F4 · kind: These shares of common stock were acquired by the reporting person through participation in the ABIOMED, Inc. Employee Stock Purchase Plan, qualified under Section 423 of the Internal Revenue Code, and the transaction was exempt under Rule 16b-3(c). F4 · shares: These shares of common stock were acquired by the reporting person through participation in the ABIOMED, Inc. Employee Stock Purchase Plan, qualified under Section 423 of the Internal Revenue Code, and the transaction was exempt under Rule 16b-3(c). Read SEC document |
| August 23, 2021 Filed Aug 25, 2021 16:37 UTC | ABIOMED INC ABMD · Entity 121309 | Disposition to issuerStock Option (Right to Buy) · Derivative | 3,492 | $0.00 Strike: $23.15 | $0.00 |
DisclosureSEC source: 0001179110-21-008415 · edgar.xml · derivative · entry 9 MINOGUE MICHAEL R · CIK 0001286370 · Director · Chairman, President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common stock · 3,492 shares Expires 2023-05-14 F2 · security: Grant to reporting person of option to buy the number of shares of Common Stock set forth in Table II, Column 7, under the ABIOMED, Inc. 2008 Stock Incentive Plan. F5 · kind: Exercise of stock options pursuant to reporting owners 10b5-1 plan. F5 · shares: Exercise of stock options pursuant to reporting owners 10b5-1 plan. F1 · derivative.exercise_date: These options become exercisable in annual 25% increments, commencing on the date shown in Table II, Column 6. Read SEC document |
| August 23, 2021 Filed Aug 25, 2021 16:37 UTC | ABIOMED INC ABMD · Entity 121309 | SaleCommon Stock $.01 par value | 3,492 | $350.00 | $1,222,200.00 |
DisclosureSEC source: 0001179110-21-008415 · edgar.xml · nonDerivative · entry 2 MINOGUE MICHAEL R · CIK 0001286370 · Director · Chairman, President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 211,635 F6 · kind: Sale of common stock pursuant to reporting owner's 10b5-1 plan. F6 · shares: Sale of common stock pursuant to reporting owner's 10b5-1 plan. F7 · price: This price represents the sale price of the transactions on the reported date at $350.0000. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer, or a security holder of the Issuer. Read SEC document |
| August 23, 2021 Filed Aug 25, 2021 16:37 UTC | ABIOMED INC ABMD · Entity 121309 | Exercise / conversionCommon Stock $.01 par value | 3,492 | $23.15 | $80,839.80 |
DisclosureSEC source: 0001179110-21-008415 · edgar.xml · nonDerivative · entry 1 MINOGUE MICHAEL R · CIK 0001286370 · Director · Chairman, President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 215,127 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · kind: Exercise of stock options pursuant to reporting owners 10b5-1 plan. F5 · shares: Exercise of stock options pursuant to reporting owners 10b5-1 plan. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.